GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia
June 27, 2024 09:15 ET
|
GT Biopharma, Inc.
GTB-3650 Phase 1 trial initiation expected in H2 2024; initial clinical data expected in H1 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in Q1 2025GTB-5550...
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results
March 26, 2024 17:00 ET
|
GT Biopharma, Inc.
Remain in active dialogue with the FDA regarding IND clearance for GTB-3650, a 2nd generation nanobody TriKE® for treatment of CD33+ leukemiaPhase 1 trial with GTB-3650 anticipated to start in 2H...
GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities
February 02, 2023 09:46 ET
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...
GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market
December 30, 2022 08:00 ET
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Dec. 30, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...